Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Viera SANDECKA"'
Autor:
Martin Stork, Eva Ondrouskova, Michaela Bohunova, Ivanna Boichuk, Dominik Fric, Zdenek Adam, Marta Krejci, Viera Sandecka, Zdenka Knechtova, Lenka Radova, Zuzana Jelinkova, Tatana Adlerova, Milan Krticka, Vladimir Nekuda, Marek Borsky, Sabina Sevcikova, Marie Jarosova, Ludek Pour
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-3 (2024)
Externí odkaz:
https://doaj.org/article/5aea7f2816d842e89d6116072aa074df
Autor:
Viera Sandecka, Tereza Popkova, Martin Stork, Vladimir Maisnar, Jiri Minarik, Alexandra Jungova, Petr Pavlicek, Lukas Stejskal, Lenka Pospisilova, Adriana Heindorfer, Jarmila Obernauerova, Evzen Gregora, Michal Sykora, Jana Ullrychova, Marek Wrobel, Petr Kessler, Tomas Jelinek, Peter Kunovszki, Sacheeta Bathija, Blanca Gros, Sabine Wilbertz, Qian Cai, Annette Lam, Ivan Spicka
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-8 (2023)
Abstract Smoldering multiple myeloma (SMM) is an asymptomatic precursor to active multiple myeloma (MM). The aim of this study was to report clinical characteristics and outcomes of patients with SMM stratified based on their risk of progression to M
Externí odkaz:
https://doaj.org/article/ac4fa0e66df54bf9a47e4350692f9954
Autor:
Martin Stork, Sabina Sevcikova, Tomas Jelinek, Jiri Minarik, Jakub Radocha, Tomas Pika, Lenka Pospisilova, Ivan Spicka, Jan Straub, Petr Pavlicek, Alexandra Jungova, Zdenka Knechtova, Viera Sandecka, Vladimir Maisnar, Roman Hajek, Ludek Pour
Publikováno v:
Biomedicines, Vol 10, Iss 10, p 2535 (2022)
In multiple myeloma (MM), malignant plasma cells infiltrate the bone marrow. In some cases, plasma cells migrate out of the bone marrow creating either para-skeletal plasmacytomas (PS) or infiltrating soft tissues as extramedullary plasmacytomas (EMD
Externí odkaz:
https://doaj.org/article/e364609dd50643da92cbb311d623a43f
Autor:
Aneta Mikulasova, Christopher P. Wardell, Alexander Murison, Eileen M. Boyle, Graham H. Jackson, Jan Smetana, Zuzana Kufova, Ludek Pour, Viera Sandecka, Martina Almasi, Pavla Vsianska, Evzen Gregora, Petr Kuglik, Roman Hajek, Faith E. Davies, Gareth J. Morgan, Brian A. Walker
Publikováno v:
Haematologica, Vol 102, Iss 9 (2017)
Monoclonal gammopathy of undetermined significance is a pre-malignant precursor of multiple myeloma with a 1% risk of progression per year. Although targeted analyses have shown the presence of specific genetic abnormalities such as IGH translocation
Externí odkaz:
https://doaj.org/article/b9c9544af99e4b429a5b86e568baa315
Autor:
Ludek Pour, Sabina Sevcikova, Henrieta Greslikova, Renata Kupska, Petra Majkova, Lenka Zahradova, Viera Sandecka, Zdenek Adam, Marta Krejci, Petr Kuglik, Roman Hajek
Publikováno v:
Haematologica, Vol 99, Iss 2 (2014)
Even in the era of new drugs, multiple myeloma patients with extramedullary relapse have a poor prognosis. Our goal was to analyze the frequency and outcome of extramedullary relapse occurring in relapsed multiple myeloma patients. In total, we analy
Externí odkaz:
https://doaj.org/article/0766d57b3426413996d8c3f579902bc9
CAR-T cells for the treatment of relapsed/refractory multiple myeloma in 2022: efficacy and toxicity
Publikováno v:
Neoplasma. 69:1008-1018
Chimeric antigen receptor (CAR)-T cells are a new treatment modality in various hematological malignancies, including relapsed/refractory multiple myeloma (RRMM). RRMM patients have a poor prognosis, and their treatment options are limited. Currently
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2256c384bb6ac64d6fbeb8734d5f275b
https://doi.org/10.4149/neo_2022_220504n477
https://doi.org/10.4149/neo_2022_220504n477
Autor:
Viera SANDECKA, Luděk POUR, Ivan ŠPIČKA, Jiří MINAŘÍK, Jakub RADOCHA, Tomáš JELÍNEK, Petr PAVLÍČEK, Alexandra JUNGOVÁ, Petr KESSLER, Marek WRÓBEL, Martin ŠTORK, Jan ŠTRAUB, Tomáš PIKA, Lenka ČÁPKOVÁ, Sabina ŠEVČÍKOVÁ, Vladimír MAISNAR, Roman HÁJEK
Publikováno v:
Neoplasma. 69(6)
We assessed the outcomes of pomalidomide and dexamethasone treatment in relapsed/refractory multiple myeloma (RRMM) patients with ≥1 prior line of therapy. We analyzed the data of all RRMM patients treated with pomalidomide and dexamethasone at nin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0549b45be2adbb252d16072e7e0e3d59
https://pubmed.ncbi.nlm.nih.gov/36591805
https://pubmed.ncbi.nlm.nih.gov/36591805
Autor:
Viera Sandecka, Tereza Popkova, Martin Stork, Vladimir Maisnar, Jiri Minarik, Alexandra Jungova, Petr Pavlicek, Lukas Stejskal, Lenka Pospisilova, Adriana Heindorfer, Jarmila Obernauerova, Evzen Gregora, Michal Sykora, Jana Ullrychova, Marek Wrobel, Petr Kessler, Hana Lukesova, Tomas Jelinek, Peter Kunovszki, Sacheeta Bathija, Blanca Gros Otero, Sabine Wilbertz, Qian Cai, Annette Lam, Ivan Špička
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S132-S133
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89e0895d5f0cebb02a2b564c60820172
https://doi.org/10.1016/s2152-2650(22)00507-9
https://doi.org/10.1016/s2152-2650(22)00507-9
